Երկիր: Կանադա
Լեզու: անգլերեն
Աղբյուրը: Health Canada
VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE)
TEVA CANADA LIMITED
N06AX16
VENLAFAXINE
75MG
CAPSULE (EXTENDED RELEASE)
VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) 75MG
ORAL
100/500
Prescription
SELECTIVE SEROTONIN AND NOREPINEPHRINE-REUPTAKE INHIBITORS
Active ingredient group (AIG) number: 0131294001; AHFS:
APPROVED
2006-10-06
_TEVA-VENLAFAXINE XR Page 1 of 88 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR TEVA-VENLAFAXINE XR Venlafaxine Hydrochloride Extended Release Capsules Extended Release Capsules, 37.5 mg, 75 mg and 150 mg venlafaxine (as venlafaxine hydrochloride), Oral USP Antidepressant / Anxiolytic Teva Canada Limited 30 Novopharm Court Toronto, ON M1B 2K9 Canada Submission Control Number: 274459 Date of Initial Authorization: OCT 06, 2006 Date of Revision: June 6, 2023 _TEVA-VENLAFAXINE XR Page 2 of 88 _ RECENT MAJOR LABEL CHANGES 7 Warnings and Precautions 10/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4 1 INDICATIONS .............................................................................................................. 4 1.1 Pediatrics .................................................................................................................... 4 1.2 Geriatrics .................................................................................................................... 4 2 CONTRAINDICATIONS ................................................................................................. 4 4 DOSAGE AND ADMINISTRATION ................................................................................. 5 4.1 Dosing Considerations ................................................................................................ 5 4.2 Recommended Dose and Dosage Adjustment .......................................................... 6 4.4 Administration ............................................................................................................ 9 4.5 Miss Կարդացեք ամբողջական փաստաթուղթը